High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: Novel hypotheses and review of literature

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 11, 2012, Pages 2553-2560

  Navab, Mohamad ^a,b   Reddy, Srinivasa T ^a,b   Van Lenten, Brian J ^b   Buga, Georgette M ^b   Hough, Greg ^b   Wagner, Alan C ^b   Fogelman, Alan M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Medicine   (United States)

Author keywords

Apolipoprotein A I; Apolipoprotein A I mimetic peptides; High density lipoprotein; Hydroxyeicosatetraenoic acid; Hydroxyoctadecadienoic acid; Lipoproteins; Oxidized lipids; Small intestine

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; APOLIPOPROTEIN A1; ARACHIDONIC ACID; ARYLDIALKYLPHOSPHATASE 1; CD36 ANTIGEN; CHOLESTEROL; FATTY ACID; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN; INITIATION FACTOR 4F; INTERLEUKIN 6; LINOLEIC ACID; LIPOXYGENASE; MYELOPEROXIDASE; NICOTINIC ACID; OLEIC ACID; PHOSPHOLIPID; STATIN (PROTEIN); ANTIINFLAMMATORY AGENT; AP 4F PEPTIDE; AP-4F PEPTIDE; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PEPTIDE;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CHRONIC INFLAMMATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIUM CELL; ENZYME ACTIVITY; HAPLORHINI; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; INTESTINE; INTESTINE FLORA; LIPID METABOLISM; LIPID OXIDATION; LIVER FIBROSIS; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RABBIT; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SEVERE ACUTE RESPIRATORY SYNDROME; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; ZEBRA FISH; ANIMAL; BLOOD VESSEL; DRUG EFFECT; IMMUNOLOGY; INFLAMMATION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; REVIEW; SMALL INTESTINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; ATHEROSCLEROSIS; BLOOD VESSELS; HUMANS; INFLAMMATION; INTESTINE, SMALL; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; PEPTIDES; PHOSPHOLIPIDS;

EID: 84871916879     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300282     Document Type: Article

References (93)

1. Lee S, Birukov KG, Romanoski CE, Springstead JR, Lusis AJ, Berliner JA. Role of phospholipid oxidation products in atherosclerosis. Circ Res. 2012;111:778-799.
2. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM. HDL and the infammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481-488.
3. Navab M, Shechter I, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM. Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol. 2010;30:164-168.
4. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, Movva R, Navab M, Fogelman AM, Rader DJ. Safety, pharmacokinet-ics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res. 2008;49:1344-1352.
5. Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, Navab M, Hama S, Hough G, Reddy ST, Soffer D, Rader DJ, Fogelman AM, Schecter A. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomark-ers of HDL function. J Lipid Res. 2011;52:361-373.
6. Navab M, Reddy ST, Anantharamaiah GM, Imaizumi S, Hough G, Hama S, Fogelman AM. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J Lipid Res. 2011;52:1200-1210.
7. Watson AD, Leitinger N, Navab M, Faull KF, Hörkkö S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder G, Fogelman AM, Berliner JA. Structural identifcation by mass spectrom-etry of oxidized phospholipids in minimally oxidized low density lipo-protein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem. 1997;272:13597-13607.
8. Subbanagounder G, Leitinger N, Schwenke DC, Wong JW, Lee H, Rizza C, Watson AD, Faull KF, Fogelman AM, Berliner JA. Determinants of bioactivity of oxidized phospholipids. Specifc oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol. 2000;20:2248-2254.
9. Boullier A, Gillotte KL, Hörkkö S, Green SR, Friedman P, Dennis EA, Witztum JL, Steinberg D, Quehenberger O. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phos-pholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem. 2000;275:9163-9169.
10. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Febbraio M, Hajjar DP, Silverstein RL, Hoff HF, Salomon RG, Hazen SL. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem. 2002;277:38517-38523.
11. Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680-2690.
12. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22:1649-1654.
13. Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, Curtiss LK, Witztum JL, Strauss BH. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 2004;109:3164-3170.
14. Tuominen A, Miller YI, Hansen LF, Kesäniemi YA, Witztum JL, Hörkkö S. A natural antibody to oxidized cardiolipin binds to oxidized low-density lipoprotein, apoptotic cells, and atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2006;26:2096-2102.
15. Tsimikas S, Aikawa M, Miller FJ Jr, Miller ER, Torzewski M, Lentz SR, Bergmark C, Heistad DD, Libby P, Witztum JL. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol. 2007;27:175-181.
16. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46-57.
17. Leibundgut G, Arai K, Orsoni A, Yin H, Scipione C, Miller ER, Koschinsky ML, Chapman MJ, Witztum JL, Tsimikas S. Oxidized phospholipids are present on plasminogen, affect fbrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol. 2012;59:1426-1437.
18. Fang L, Harkewicz R, Hartvigsen K, Wiesner P, Choi SH, Almazan F, Pattison J, Deer E, Sayaphupha T, Dennis EA, Witztum JL, Tsimikas S, Miller YI. Oxidized cholesteryl esters and phospholipids in zebrafsh larvae fed a high cholesterol diet: macrophage binding and activation. J Biol Chem. 2010;285:32343-32351.
19. Fang L, Green SR, Baek JS, Lee SH, Ellett F, Deer E, Lieschke GJ, Witztum JL, Tsimikas S, Miller YI. In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafsh. J Clin Invest. 2011;121:4861-4869.
20. Imai Y, Kuba K, Neely GG, et al. Identifcation of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133:235-249.
21. Crowe CR, Chen K, Pociask DA, Alcorn JF, Krivich C, Enelow RI, Ross TM, Witztum JL, Kolls JK. Critical role of IL-17RA in immunopathol-ogy of infuenza infection. J Immunol. 2009;183:5301-5310.
22. Ikeda K, Mutoh M, Teraoka N, Nakanishi H, Wakabayashi K, Taguchi R. Increase of oxidant-related triglycerides and phosphatidylcholines in serum and small intestinal mucosa during development of intestinal polyp formation in Min mice. Cancer Sci. 2011;102:79-87.
23. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H. Oxidative damage in multiple sclerosis lesions. Brain. 2011;134(Pt 7):1914-1924.
24. Cruz D, Watson AD, Miller CS, Montoya D, Ochoa MT, Sieling PA, Gutierrez MA, Navab M, Reddy ST, Witztum JL, Fogelman AM, Rea TH, Eisenberg D, Berliner J, Modlin RL. Host-derived oxidized phos-pholipids and HDL regulate innate immunity in human leprosy. J Clin Invest. 2008;118:2917-2928.
25. Ikura Y, Ohsawa M, Suekane T, Fukushima H, Itabe H, Jomura H, Nishiguchi S, Inoue T, Naruko T, Ehara S, Kawada N, Arakawa T, Ueda M. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology. 2006;43:506-514.
26. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Anantharamaiah GM, Fogelman AM. Anti-infammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affnity than human apoA-I. J Lipid Res. 2008;49:2302-2311.
27. DeLeve LD, Wang X, Kanel GC, Atkinson RD, McCuskey RS. Prevention of hepatic fbrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis. Am J Pathol. 2008;173:993-1001.
28. Suzuki M, Kamei M, Itabe H, Yoneda K, Bando H, Kume N, Tano Y. Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration. Mol Vis. 2007;13:772-778.
29. Weihrauch D, Xu H, Shi Y, Wang J, Brien J, Jones DW, Kaul S, Komorowski RA, Csuka ME, Oldham KT, Pritchard KA. Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial infammation, and angiogenic potential in tight-skin mice. Am J Physiol Heart Circ Physiol. 2007;293:H1432-H1441.
30. Leitinger N, Tyner TR, Oslund L, Rizza C, Subbanagounder G, Lee H, Shih PT, Mackman N, Tigyi G, Territo MC, Berliner JA, Vora DK. Structurally similar oxidized phospholipids differentially regulate endo-thelial binding of monocytes and neutrophils. Proc Natl Acad Sci USA. 1999;96:12010-12015.
31. Napoli C, Witztum JL, Calara F, de Nigris F, Palinski W. Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses. Circ Res. 2000;87:946-952.
32. Furnkranz A, Schober A, Bochkov VN, Bashtrykov P, Kronke G, Kadl A, Binder BR, Weber C, Leitinger N. Oxidized phospholipids trigger atherogenic infammation in murine arteries. Arterioscler Thromb Vasc Biol. 2005;25:633-638.
33. Huber J, Fürnkranz A, Bochkov VN, Patricia MK, Lee H, Hedrick CC, Berliner JA, Binder BR, Leitinger N. Specifc monocyte adhesion to endothelial cells induced by oxidized phospholipids involves activation of cPLA2 and lipoxygenase. J Lipid Res. 2006;47:1054-1062.
34. Honda HM, Leitinger N, Frankel M, Goldhaber JI, Natarajan R, Nadler JL, Weiss JN, Berliner JA. Induction of monocyte binding to endothe-lial cells by MM-LDL: role of lipoxygenase metabolites. Arterioscler Thromb Vasc Biol. 1999;19:680-686.
35. Patricia MK, Kim JA, Harper CM, Shih PT, Berliner JA, Natarajan R, Nadler JL, Hedrick CC. Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:2615-2622.
36. Griesser M, Suzuki T, Tejera N, Mont S, Boeglin WE, Pozzi A, Schneider C. Biosynthesis of hemiketal eicosanoids by cross-over of the 5-lipoxygenase and cyclooxygenase-2 pathways. Proc Natl Acad Sci USA. 2011;108:6945-6950.
37. Harkewicz R, Hartvigsen K, Almazan F, Dennis EA, Witztum JL, Miller YI. Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized low density lipoprotein. J Biol Chem. 2008;283:10241-10251.
38. Berliner JA, Gharavi NM. Endothelial cell regulation by phospholipid oxidation products. Free Radic Biol Med. 2008;45:119-123.
39. Berliner JA, Leitinger N, Tsimikas S. The role of oxidized phospholipids in atherosclerosis. J Lipid Res. 2009;50 Suppl:S207-S212.
40. Lee S, Gharavi NM, Honda H, Chang I, Kim B, Jen N, Li R, Zimman A, Berliner JA. A role for NADPH oxidase 4 in the activation of vascular endothelial cells by oxidized phospholipids. Free Radic Biol Med. 2009;47:145-151.
41. Zimman A, Chen SS, Komisopoulou E, Titz B, Martínez-Pinna R, Kaf A, Berliner JA, Graeber TG. Activation of aortic endothelial cells by oxidized phospholipids: a phosphoproteomic analysis. J Proteome Res. 2010;9:2812-2824.
42. Romanoski CE, Che N, Yin F, Mai N, Pouldar D, Civelek M, Pan C, Lee S, Vakili L, Yang WP, Kayne P, Mungrue IN, Araujo JA, Berliner JA, Lusis AJ. Network for activation of human endothelial cells by oxidized phospholipids: a critical role of heme oxygenase 1. Circ Res. 2011;109:e27-e41.
43. Kadl A, Sharma PR, Chen W, Agrawal R, Meher AK, Rudraiah S, Grubbs N, Sharma R, Leitinger N. Oxidized phospholipid-induced infammation is mediated by Toll-like receptor 2. Free Radic Biol Med. 2011;51:1903-1909.
44. Birukova AA, Lee S, Starosta V, Wu T, Ho T, Kim J, Berliner JA, Birukov KG. A role for VEGFR2 activation in endothelial responses caused by barrier disruptive OxPAPC concentrations. PLoS ONE. 2012;7:e30957.
45. Starosta V, Wu T, Zimman A, Pham D, Tian X, Oskolkova O, Bochkov V, Berliner JA, Birukova AA, Birukov KG. Differential regulation of endo-thelial cell permeability by high and low doses of oxidized 1-palmitoyl-2-arachidonyl- sn-glycero-3-phosphocholine. Am J Respir Cell Mol Biol. 2012;46:331-341.
46. Lee S, Springstead JR, Parks BW, Romanoski CE, Palvolgyi R, Ho T, Nguyen P, Lusis AJ, Berliner JA. Metalloproteinase processing of HBEGF is a proximal event in the response of human aortic endothe-lial cells to oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2012;32:1246-1254.
47. Springstead JR, Gugiu BG, Lee S, Cha S, Watson AD, Berliner JA. Evidence for the importance of OxPAPC interaction with cysteines in regulating endothelial cell function. J Lipid Res. 2012;53:1304-1315.
48. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, Boullier A, Gonen A, Diehl CJ, Que X, Montano E, Shaw PX, Tsimikas S, Binder CJ, Witztum JL. Oxidation-specifc epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res. 2011;108:235-248.
49. Kim JB, Xia YR, Romanoski CE, Lee S, Meng Y, Shi YS, Bourquard N, Gong KW, Port Z, Grijalva V, Reddy ST, Berliner JA, Lusis AJ, Shih DM. Paraoxonase-2 modulates stress response of endothelial cells to oxidized phospholipids and a bacterial quorum-sensing molecule. Arterioscler Thromb Vasc Biol. 2011;31:2624-2633.
50. Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, Johnstone SR, Elliott MR, Gruber F, Han J, Chen W, Kensler T, Ravichandran KS, Isakson BE, Wamhoff BR, Leitinger N. Identifcation of a novel macro-phage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res. 2010;107:737-746.
51. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41:1495-1508.
52. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM. The oxidation hypothesis of ath-erogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45:993-1007.
53. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah GM, Hui EK, Nayak DP, Fogelman AM. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the infammatory response induced by infuenza A infection of human type II pneumocytes. Circulation. 2004;110:3252-3258.
54. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, Nayak DP, Hama S, Navab M, Fogelman AM. Infuenza infection promotes macrophage traffc into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation. 2002;106:1127-1132.
55. Gharavi NM, Gargalovic PS, Chang I, Araujo JA, Clark MJ, Szeto WL, Watson AD, Lusis AJ, Berliner JA. High-density lipoprotein modulates oxidized phospholipid signaling in human endothelial cells from proinfammatory to anti-infammatory. Arterioscler Thromb Vasc Biol. 2007;27:1346-1353.
56. Miyoshi M, Nakano Y, Sakaguchi T, Ogi H, Oda N, Suenari K, Kiyotani K, Ozono R, Oshima T, Yoshida T, Chayama K. Gene delivery of para-oxonase-1 inhibits neointimal hyperplasia after arterial balloon-injury in rabbits fed a high-fat diet. Hypertens Res. 2007;30:85-91.
57. Elsøe S, Ahnström J, Christoffersen C, Hoofnagle AN, Plomgaard P, Heinecke JW, Binder CJ, Björkbacka H, Dahlbäck B, Nielsen LB. Apolipoprotein M binds oxidized phospholipids and increases the anti-oxidant effect of HDL. Atherosclerosis. 2012;221:91-97.
58. Buga GM, Frank JS, Mottino GA, Hakhamian A, Narasimha A, Watson AD, Yekta B, Navab M, Reddy ST, Anantharamaiah GM, Fogelman AM. D-4F reduces EO6 immunoreactivity, SREBP-1c mRNA levels, and renal infammation in LDL receptor-null mice fed a Western diet. J Lipid Res. 2008;49:192-205.
59. Imaizumi S, Grijalva V, Navab M, Van Lenten BJ, Wagner AC, Anantharamiah GM, Fogelman AM, Reddy ST. L-4F differentially alters plasma levels of oxidized fatty acids resulting in more anti-infammatory HDL in mice. Drug Metab Lett. 2010;4:139-148.
60. Wool GD, Cabana VG, Lukens J, Shaw PX, Binder CJ, Witztum JL, Reardon CA, Getz GS. 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. FASEB J. 2011;25:290-300.
61. Getz GS, Reardon CA. Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis. J Infamm Res. 2011;4:83-92.
62. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-infammatory HDL becomes pro-infammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758-2767.
63. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan ML, Lusis AJ, Fogelman AM, La Du BN. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99:2005-2019.
64. Hedrick CC, Hassan K, Hough GP, Yoo JH, Simzar S, Quinto CR, Kim SM, Dooley A, Langi S, Hama SY, Navab M, Witztum JL, Fogelman AM. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler Thromb Vasc Biol. 2000;20:1946-1952.
65. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res. 2001;42:1308-1317.
66. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, Hough G, Bachini E, Grijalva VR, Wagner AC, Shaposhnik Z, Fogelman AM. The double jeopardy of HDL. Ann Med. 2005;37:173-178.
67. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinfammatory properties of HDL. J Clin Invest. 2007;117:746-756.
68. Green PS, Vaisar T, Pennathur S, Kulstad JJ, Moore AB, Marcovina S, Brunzell J, Knopp RH, Zhao XQ, Heinecke JW. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation. 2008;118:1259-1267.
69. McMahon M, Skaggs BJ, Sahakian L, Grossman J, FitzGerald J, Ragavendra N, Charles-Schoeman C, Chernishof M, Gorn A, Witztum JL, Wong WK, Weisman M, Wallace DJ, La Cava A, Hahn BH. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with infamma-tory oxidised lipids. Ann Rheum Dis. 2011;70:1619-1624.
70. Charles-Schoeman C, Lee Y Y, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, Taylor M, McMahon M, Paulus HE, Reddy ST. Cholesterol effux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012;71:1157-1162.
71. Mastorikou M, Mackness M, Mackness B. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes. Diabetes. 2006;55:3099-3103.
72. Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, Fogelman AM, Ferrannini E, Reddy ST. Anti-infammatory and antioxi-dant properties of HDLs are impaired in type 2 diabetes. Diabetes. 2011;60:2617-2623.
73. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol. 2010;21:312-318.
74. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265-1276.
75. Undurti A, Huang Y, Lupica JA, Smith JD, DiDonato JA, Hazen SL. Modifcation of high density lipoprotein by myeloperoxidase generates a pro-infammatory particle. J Biol Chem. 2009;284:30825-30835.
76. Watanabe J, Grijalva V, Hama S, Barbour K, Berger FG, Navab M, Fogelman AM, Reddy ST. Hemoglobin and its scavenger protein hap-toglobin associate with apoA-1-containing particles and infuence the infammatory properties and function of high density lipoprotein. J Biol Chem. 2009;284:18292-18301.
77. Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, Lee TD, Reddy ST. Proteomic profling following immunoaffnity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinfammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 2012;64:1828-1837.
78. Shao B, Pennathur S, Pagani I, Oda MN, Witztum JL, Oram JF, Heinecke JW. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol effux by the ABCA1 pathway. J Biol Chem. 2010;285:18473-18484.
79. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693-2708.
80. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol effux capacity, high-density lipo-protein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
81. Heinecke J. HDL and cardiovascular-disease risk-time for a new approach? N Engl J Med. 2011;364:170-171.
82. Cavigiolio G, Geier EG, Shao B, Heinecke JW, Oda MN. Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins. J Biol Chem. 2010;285:18847-18857.
83. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM, Parks JS, Kuipers F, Hayden MR. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116:1052-1062.
84. Green PH, Glickman RM, Saudek CD, Blum CB, Tall AR. Human intestinal lipoproteins. Studies in chyluric subjects. J Clin Invest. 1979;64:233-242.
85. Wang Z, Klipfell E, Bennett BJ, et al. Gut fora metabolism of phospha-tidylcholine promotes cardiovascular disease. Nature. 2011;472:57-63.
86. Navab M, Reddy ST, Anantharamaiah GM, Hough G, Buga GM, Danciger J, Fogelman AM. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased infammation in low-density lipoprotein receptor-null mice. J Lipid Res. 2012;53:437-445.
87. Adler DH, Cogan JD, Phillips JA 3rd, Schnetz-Boutaud N, Milne GL, Iverson T, Stein JA, Brenner DA, Morrow JD, Boutaud O, Oates JA. Inherited human cPLA(2alpha) defciency is associated with impaired eicosanoid biosynthesis, small intestinal ulceration, and platelet dysfunction. J Clin Invest. 2008;118:2121-2131.
88. Montrose DC, Kadaveru K, Ilsley JN, Root SH, Rajan TV, Ramesh M, Nichols FC, Liang BT, Sonin D, Hand AR, Zarini S, Murphy RC, Belinsky GS, Nakanishi M, Rosenberg DW. cPLA2 is protective against COX inhibitor-induced intestinal damage. Toxicol Sci. 2010;117:122-132.
89. Watanabe J, Lin JA, Narasimha AJ, Shahbazian A, Ishikawa TO, Martin MG, Herschman HR, Reddy ST. Novel anti-infammatory functions for endothelial and myeloid cyclooxygenase-2 in a new mouse model of Crohn's disease. Am J Physiol Gastrointest Liver Physiol. 2010;298:G842-G850.
90. van Leuven SI, Hezemans R, Levels JH, Snoek S, Stokkers PC, Hovingh GK, Kastelein JJ, Stroes ES, de Groot E, Hommes DW. Enhanced ath-erogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res. 2007;48:2640-2646.
91. Rao J, DiGiandomenico A, Artamonov M, Leitinger N, Amin AR, Goldberg JB. Host derived infammatory phospholipids regulate rahU (PA0122) gene, protein, and bioflm formation in Pseudomonas aerugi-nosa. Cell Immunol. 2011;270:95-102.
92. Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, Imaizumi S, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther. 2012;11:1311-1319.
93. Su F, Kozak KR, Imaizumi S, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA. 2010;107:19997-20002.